Ocular renin-angiotensin system with special reference in the anterior part of the eye

作     者：Mervi Holappa Heikki Vapaatalo Anu Vaajanen 

作者机构：BioMediTechUniversity of Tampere Institute of BiomedicinePharmacologyUniversity of Helsinki Department of OphthalmologyTampere University Hospital SILKDepartment of OphthalmologySchool of MedicineUniversity of Tampere 

出 版 物：《World Journal of Ophthalmology》 (世界眼科杂志)

年 卷 期：2015年第5卷第3期

页      面：110-124页

学科分类：1002[医学-临床医学] 100212[医学-眼科学] 10[医学] 

基　　金：Supported by Päivikki and Sakari Sohlberg Foundation the Eye Foundation the Glaucoma Research Foundation Lux the Competitive Research Funding of Tampere University Hospital,No.9S072 and the Foundation for Clinical Chemistry Research 

主　　题：Angiotensin converting enzyme 1 Angiotensin converting enzyme 2 Angiotensin converting enzyme-inhibitors AngiotensinⅡ Angiotensin(1-9) Angiotensin(1-7) Glaucoma Intraocular pressure Renin-angiotensin system 

摘      要：The renin-angiotensin system(RAS) regulates blood pressure(BP) homeostasis, systemic fluid volume and electrolyte balance. The RAS cascade includes over twenty peptidases, close to twenty angiotensin peptides and at least six receptors. Out of these, angiotensin Ⅱ, angiotensin converting enzyme 1 and angiotensin Ⅱ type 1 receptor(AngⅡ-ACE1-AT1R) together with angiotensin(1-7), angiotensin converting enzyme 2 and Mas receptor(Ang(1-7)-ACE2-Mas R) are regarded as the main components of RAS. In addition to circulating RAS, local RA-system exists in various organs. Local RA-systems are regarded as tissue-specific regulatory system accounting for local effects and long term changes in different organs. Many of the central components such as the two main axes of RAS: AngⅡ-ACE1-AT1 R and Ang(1-7)-ACE2-Mas R, have been identified in the human eye. Furthermore, it has been shown that systemic antihypertensive RAS- inhibiting medications lower intraocular pressure(IOP). These findings suggest the crucial role of RAS not only in the regulation of BP but also in the regulation of IOP, and RAS potentially plays a role in the development of glaucoma and antiglaucomatous drugs.